Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Almost up 10% on good volume....whats propelling this dog today?
Ha, just seeing this now!
We ARE. Wry close, revenues keep going up exponentially, this may be a good time to double down
Seems to be waking up a bit now. Of course the overall market has turned up so that could be pulling it up as well. Waiting for that next rumor.
nothing moves this stock unless there is a buyout rumor!
So far market taking this news and yawning.
Wow we moved up to # 2 on the trend list!!! It’s Wednesday night at 10:41. You can’t tell me or maybe you can that the possibility of maybe AUPH n Otsuka may not attend the JPM conferences next week?
Here is another one AZN buys out Gracell.
Not a single competition on the radar screen. The latest one by Novartis was discontinued. This is probably the reason for PG’s intransigence on his stance about the BO price. Honestly, at this time, I couldn’t care less if it’s not bought soon. We have a gem of a drug without any competition in sight , BIC & FIC for this unmet medical need.
Merry Christmas and a happy new to my friends here especially Cervelo, Ho Ho Ho.
So sorry! do you think he’ll haunt us for a thousand years? My bad.
you awoke the beast! -True
Hehehe, let sleeping dogs lie eh, lol. Anyway, I like what he said about UNCY. I’m tempted about it but if I do, it will just be spare change as he said, money that you can afford to lose and not look back. Ganzie, we’re very close I think here at Auphie land or Auphistan as they call it in central Asia.
I totally agree on that Jess, BUT I knew once you mentioned Whatalene, he’d fire back numerous comments, you awoke the beast!
Ganz, what he said is true. The stoppage of NVS LN trial adds more oomphs, however infinitely small it is(maybe a quark size, lol) to the BO side. Short story, the news doesn’t hurt us one iota.
Can’t believe an ol’ seasoned pro like you took the bait on this one, ha!
Kiwi,
Appreciate the response. Still own my ARDX. 3/4 of position bought in mid-3s but continued to take nibbles in the 4s, 5s, and 6s ... and closed some calls along the way, giving up my premiums. Oiy! It always seems to be an ugly path. But happy where I sit today. Currently expect to sit on my holdings for LT gains at some point.
Auph: it will be fine. Auph a premium generating machine with cash secured puts and covered calls.
UNCY: I will take a look at this one and get back to you on that board.
Side Q: what's going on with BB scripts? Someone suggested that script data will no longer be provided by BB ... perhaps a dispute about publication on msg boards? Any insights?
WT
WT
WT. I like your ARDX position better :--)
NVS terminating their LN trial is a major positive for AUPH tho. Makes it more likely BP might get interested.
Don't have a position in AUPH and ARDX has done nothing but go up since I sold it :--(
I have been doing some DD on UNCY so if interested in why ...ask me on that board .
Kiwi
A lot of good news appears to be building up for Auph:
(a) NVS terminates LN trial, (b) Eular recommendations and guidelines, (c) treatment period per Eular guidelines trending to 3 years, (c) some apparently seeing Medicare issuing very liberal approvals for use of VOC treatment protocol (per Lorddragon on X), (d) Otsuka EU sales appear to be strong ... appears to have added 3K to 5K patients in only its second Q of sales in EU (per derived by Lorddragon on X from Otsuka's royalty payments to Auph). WT
Jess. well thx for the invite ( to get in on AUPH ), but I'll pass for now.
My wife sees the occasional LN patients and finds payer resistance to Lupy's price, results in only those with severe LN (..continuing decline in kidney function on SOC...last chance before dialysis etc ) getting coverage .
Failure of Costentyx in treating LN does up your chances of a buyout tho
I have small positions in VKTX and UNCY ( in biotech ) but most of my portfolio has been AI related for most of 2023 ...AMZN , NVDA , MSFT , VRT etc , CRWD for cyber security etc .
I still have a position in SWAV but my only big biotech winner this year was SLNO . ARDX was a win but off set by a loss in AMRN ( slow sales Vazkepa in the UK )
UNCY is my high risk speculative ( risk only what U can afford to lose ) biotech position for 2024
Good luck
Kiwi
Kiwi, thanks for sharing. It’s still low here. You can still get in and perhaps double it quite soon…jmo.
Well your chances look better now .
This Cosentyx trial in LN was recently stopped for futility
We should see the $12 area shortly.
Personally, I think a buyout will not occur until price gets to $10-15 (closer to 15) and the BO price will be $28 plus or minus $5.
Jess what price do you think AUPH can be bought for thanks
finally you admitted your foolish aria target. Don’t you worry, we’ll rack up some wads of ka ching here, again very soon, just like Aria, unless you didn’t buy back again.
Jess, I wholeheartedly agree with you on the notion that we will never visit my foolish target of many years ago. But, place a 1 in front of it and we will pass that as well..
Hopefully this is the beginning of a nice move up in price and there is something positive behind it. Awfully quiet about this strategic review.
anyone here looking at CCCC the stock was a buck and change monday now over $6.00 and still running
Newbie, hey who knows, maybe the next PR from the management is a request tor the FDA to consider LUPY for SLE This would be the mother of all speculation, lol. It’s a waiting game now, definitely not going down to BR’s fav figure.
I know they dont know much, but $13-$15. Puke city. Jess- I need some encouragement please.
What is #5?
Could we see a pump out of Jess to start this trading day?
Not a question about reading anyone’s mind, just look at the data concerning buyouts. Jess was surprised at that buyout in a company before drug approval but he shouldn’t be. The evidence is there for anyone to see and willing to admit.
Zz, I think you miss #5.
I believe it has been pointed out before that the vast majority of buyouts (in the biotech space) occur around (both before and just after phase III readouts). That way the BP can do the rollout as they wish - properly. That is why there was so much speculation with Aurinia back then. The longer the time passes and the more any rollout trips over itself, the less any BP stays interested.
WOW! They don’t even have an approved drug yet. There are two in P3.
“ guess i'll check back in a year.”
I don’t think you can stand not bashing PG & management in one week or two or month. It will be an unbelievable miracle if it happens.
so you are happy with 34.00 down to 4.53 and a rebound to 8.67 gets your panties all excited. some of you need to look in the mirror and say duh.
I guess if you don't suck peter here your opinion does not matter.
seems to be a board of left wing democrats here living in their socialist world
guess i'll check back in a year.
“Simply amazing”, we’re running out of accolades for this guy.
Colorblind also? What a record you've achieved!
December 23rd close was $4.53, so GREEN for the year, another Christmas color.
WRONG AGAIN!
At least you are incredibly consistent!
Simply amazing!
On a positive note for the Christmas season.
RED is a holiday color.
Just petes little gift to the shareholders.
Rumors about Gilead could be true as their collaboration with Galapagos NV on systemic sclerosis treatment is no longer in play since two years ago. Auph drug is proven useful in this indication. Maybe another ka Ching factor in the BO? Hey, who knows….
——————————-
“We are very disappointed not to be able to bring a novel medication to patients suffering from such a devastating disease with high unmet need. We would like to thank the patients and the medical professionals who participated in the ISABELA studies and contributed to the advancement of IPF research. We intend to learn from this data in our continued commitment to develop therapies in IPF and fibrosis,” said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.
“We are extremely disappointed by this news. Despite this setback, we remain committed to leveraging our novel target research engine and strong cash balance to discover potential therapies for IPF and fibrosis,” said Onno van de Stolpe, CEO of Galapagos.
Ziritaxestat (GLPG1690) is an investigational autotaxin inhibitor discovered by Galapagos. Gilead in-licensed ex-European rights to ziritaxestat in July 2019 and commenced sharing the Phase 3 development costs.
All clinical trials with ziritaxestat, including the long-term extension of the Phase 2a NOVESA trial in systemic sclerosis, will be discontinued.”
Wouldn't that require testes?
Your advice is great, but unfortunately probably not for that person (might be a guy but so fearful perhaps not).
Cheers!
Happy thanksgiving to everybody including the 12.50 guy.
Jess, Your generosity continues.........nice to see such positivity in a 'world gone mad'.
I appreciate your outlook and agree that even that big fat turkey should receive a pardon today!
Cheers!
Happy Thanksgiving to all
Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis
Nov. 22, 2023
https://www.bioworld.com/articles/703042-aurinia-therapeutics-aur-300-proven-useful-in-systemic-sclerosis?v=preview
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |